Objectives To assess the effects of early management of hyperglycaemia with antidiabetic drugs plus lifestyle intervention compared with lifestyle alone, on microvascular function in adults with pre-diabetes.

Technological progress and digital transformation, which began with Big Data and Artificial Intelligence (AI), are currently transforming ways of working in all fields, to support decision-making, particularly in multicenter research. This study analyzed a sample of 5178 hospital patients, suffering from exacerbation of chronic obstructive pulmonary disease (eCOPD). Because of differences in disease stages and progression, the clinical pathologies and characteristics of the patients were extremely diverse. Our objective was thus to reduce dimensionality by projecting the data onto a lower dimensional subspace. The results obtained show that principal component analysis (PCA) is the most effective linear technique for dimensionality reduction. Four patient profile groups are generated with similar affinity and characteristics. In conclusion, dimensionality reduction is found to be an effective technique that permits the visualization of early indications of clinical patterns with similar characteristics. This is valuable since the development of other pathologies (chronic diseases) over any given time period influences clinical parameters. If healthcare professionals can have access to such information beforehand, this can significantly improve the quality of patient care, since this type of study is based on a multitude of data-variables that can be used to evaluate and monitor the clinical status of the patient.

Objective: To compare the effect of glucose-lowering drugs on peripheral nerve and kidney function in prediabetes. Methods: Multicenter, randomized, placebo-controlled trial in 658 adults with prediabetes treated for 1 year with metformin, linagliptin, their combination or placebo. Endpoints are small fiber peripheral neuropathy (SFPN) risk estimated by foot electrochemical skin conductance (FESC < 70 μSiemens) and estimated glomerular filtration rate (eGFR). Results: Compared to the placebo, the proportion of SFPN was reduced by 25.1% (95% CI:16.3–33.9) with metformin alone, by 17.3% (95% CI 7.4–27.2) with linagliptin alone, and by 19.5% (95% CI 10.1–29.0) with the combination linagliptin/metformin (p < 0.0001 for all comparisons). eGFR remained +3.3 mL/min (95% CI: 0.38–6.22) higher with the combination linagliptin/metformin than with the placebo (p = 0.03). Fasting plasma glucose (FPG) decreased more with metformin monotherapy −0.3 mmol/L (95%CI: −0.48; 0.12, p = 0.0009) and with the combination metformin/linagliptin −0.2 mmol/L (95% CI: −0.37; −0.03) than with the placebo (p = 0.0219). Body weight (BW) decreased by −2.0 kg (95% CI: −5.65; −1.65, p = 0.0006) with metformin monotherapy, and by −1.9 kg (95% CI: −3.02; −0.97) with the combination metformin/linagliptin as compared to the placebo (p = 0.0002). Conclusions: in people with prediabetes, a 1 year treatment with metformin and linagliptin, combined or in monotherapy, was associated with a lower risk of SFPN, and with a lower decrease in eGFR, than treatment with placebo.